Morgan Stanley lowers Paychex price target on higher debt concerns

Morgan Stanley and Stifel both reduced price targets for Paychex (PAYX) following its Q4 FY25 results and FY26 guidance. Morgan Stanley lowered its target to $148, citing concerns over Paychex's increased net debt post-Paycor acquisition and potential core business deceleration, leading to a lower applied valuation multiple despite higher projected earnings. Stifel, which cut its target to $152, noted that the company's fiscal 2026 organic revenue growth guidance of 4.5-5.5% fell short of analyst expectations, despite Q4 EPS aligning with forecasts and strong overall revenue growth. This indicates a cautious analyst outlook driven by valuation concerns tied to debt and organic growth trajectory, even as overall revenue is boosted by acquisitions.

Analysis

Recent analyst actions from Morgan Stanley and Stifel reveal a cautious outlook on Paychex (PAYX), despite the company reporting a 10% year-over-year revenue increase to $1.43 billion in its fourth quarter. The primary concern is the divergence between strong, acquisition-fueled headline growth and a potential slowdown in the core business. Morgan Stanley lowered its price target to $148, not because of poor earnings estimates—which they actually raised for fiscal years 2026 and 2027 to incorporate the Paycor acquisition—but due to a lower valuation multiple of 25 times (down from 27x). This multiple compression is explicitly tied to Paychex's "highest-ever net debt position" post-acquisition and fears of decelerating core operations. Similarly, Stifel reduced its target to $152 after Paychex guided for fiscal 2026 organic revenue growth of 4.5-5.5%, missing the 5.8% analyst consensus, even though its overall revenue guidance of 16.5-18.5% growth and EPS outlook were strong. This indicates the market is looking past the inorganic top-line boost and focusing on fundamental risks, questioning whether the stock's premium P/E ratio of 28.5x is sustainable given the new leverage and softer organic growth trajectory.

Key Decisions for Investors

• Investors should scrutinize the disparity between the high total revenue growth guidance of 16.5-18.5% and the weaker organic growth forecast of 4.5-5.5%, as this gap highlights analyst concerns about the health of the core business.
• Re-evaluate the stock's premium 28.5x P/E ratio in the context of analyst valuation multiple contractions, which are being driven by the company's significantly increased leverage and slowing organic growth.
• Closely monitor the company's balance sheet and cash flow statements in coming quarters to assess the real-world impact of its 'highest-ever net debt position' on financial flexibility and interest coverage.